Stock comparison
Moderna, Inc. is 3.3x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($30.38 B vs $9.33 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 3.3x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($30.38 B vs $9.33 B).
Market value leader
MRNA
Moderna, Inc. is 3.3x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($30.38 B vs $9.33 B).
Revenue leader
MRNA
HALO: $1.40B vs MRNA: $1.94B.
Profit leader
HALO
HALO: $316.89M vs MRNA: -$2.82B.
Margin leader
HALO
HALO: 22.7% vs MRNA: -145.2% net margin.
| Metric | HALO | MRNA |
|---|---|---|
| Market cap | $9.33 B | $30.38 B |
| US-listed rank | #998 | #461 |
| Revenue (latest FY) | $1.40B | $1.94B |
| Net income (latest FY) | $316.89M | -$2.82B |
| Net margin | 22.7% | -145.2% |
| P/E (trailing FY) | 29.4x | - |
| SEC filings | 1,479 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 3.3x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($30.38 B vs $9.33 B).
In their latest fiscal years, HALOZYME THERAPEUTICS, INC. reported $1.40B in revenue while Moderna, Inc. reported $1.94B.
Full pages: HALOZYME THERAPEUTICS, INC. and Moderna, Inc., or browse the full rankings.